Adocia (ADOC)

Currency in EUR
3.97
-0.03(-0.80%)
Real-time Data·
ADOC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.964.07
52 wk Range
3.6112.40
Key Statistics
Prev. Close
4
Open
4.02
Day's Range
3.96-4.07
52 wk Range
3.61-12.4
Volume
22.21K
Average Volume (3m)
172.11K
1-Year Change
-44.6089%
Book Value / Share
0.08
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ADOC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.70
Upside
+144.33%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

Adocia News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Analyst Ratings

3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 9.70
(+144.33% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Stifel
Buy10.00+151.89%11.00MaintainJul 06, 2026
Stifel
Buy11.00+177.08%12.00MaintainMay 13, 2026

Earnings

Latest Release
May 12, 2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ADOC Income Statement

Compare ADOC to Peers and Sector

Metrics to compare
ADOC
Peers
Sector
Relationship
P/E Ratio
−4.7x−2.8x−0.3x
PEG Ratio
0.10−0.020.00
Price/Book
52.5x−0.3x2.6x
Price / LTM Sales
20.3x16.2x3.0x
Upside (Analyst Target)
175.0%239.0%56.6%
Fair Value Upside
Unlock6.5%10.2%Unlock

Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of pramlintide and lispro, as well as M1Pram, a combination of insulin M1 and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity, including AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and AdoGel Sema for the long-acting drug delivery of semaglutide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
335.81K1.72%1.35M
Other Institutional Investors
4.86M24.84%19.53M
Public Companies & Retail Investors
14.37M73.45%57.74M
Total
19.57M100.00%78.62M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Vester Finance9.08%1,775,7807,135
Heights Capital Management, Inc.4.89%957,6093,848

People Also Watch

2.183
VLS
+0.83%
112.80
ABVX
+3.96%
35.00
NANOB
+3.37%
7.54
ALKAL
+1.62%

FAQ

What Is the Adocia (ADOC) Stock Price Today?

The Adocia stock price today is 3.97 EUR.

What Stock Exchange Does Adocia Trade On?

Adocia is listed and trades on the Paris Stock Exchange.

What Is the Stock Symbol for Adocia?

The stock symbol for Adocia is "ADOC."

What Is the Adocia Market Cap?

As of today, Adocia market cap is 77.87M EUR.

What Is Adocia's Earnings Per Share (TTM)?

The Adocia EPS (TTM) is -0.93.

When Is the Next Adocia Earnings Date?

Adocia will release its next earnings report on Sep 24, 2026.

From a Technical Analysis Perspective, Is ADOC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Adocia Stock Split?

Adocia has split 0 times.

How Many Employees Does Adocia Have?

Adocia has 73 employees.

What is the current trading status of Adocia (ADOC)?

As of Jul 31, 2026, Adocia (ADOC) is trading at a price of 3.97 EUR, with a previous close of 4.00 EUR. The stock has fluctuated within a day range of 3.96 EUR to 4.07 EUR, while its 52-week range spans from 3.61 EUR to 12.40 EUR.

What Is Adocia (ADOC) Price Target According to Analysts?

The average 12-month price target for Adocia is 9.70 EUR, with a high estimate of 12 EUR and a low estimate of 4.8 EUR. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +144.33% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.